Boardroom Alpha
Boardroom Alpha
SCLX · Additional Proxy Materials (DEFA14A) · Filed May 5, 2026

Scilex Holding Co — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 5, 2026
Ticker
SCLX
Accession
0001193125-26-206367
Boardroom Alpha · Filing insights

Scilex corrects voting threshold for Proposal No. 3 and discloses plan to increase authorized shares under the 2022 Plan.

About Scilex Holding Co
Market cap
$63M
1Y TSR
+36.9%
3Y TSR
−68.3%
Board grade
D
Sector
Healthcare
CEO
Henry Ji
Last annual meeting: Jun 24, 2026 · View full Scilex Holding Co profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

SCILEX HOLDING COMPANY

(Name of Registrant as Specified in Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 
 


Supplement to the Proxy Statement for the Annual Meeting of Stockholders

The following information relates to and supplements the definitive proxy statement (the “Proxy Statement”) of Scilex Holding Company (the “Company”), furnished to stockholders of the Company in connection with the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) to be held virtually at www.virtualshareholdermeeting.com/SCLX2026 on June 24, 2026, at 9:00 a.m. (Pacific Time), which was filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2026.

This supplement to the Proxy Statement is being filed to correct the disclosure in the sections titled (i) “Procedural Matters—How many votes are needed for approval of each proposal?” set forth on page 3 of the Proxy Statement with respect to Proposal No. 3, and (ii) “Proposal No. 3 — Approval of the Amendment to the 2022 Plan—Vote Required” set forth on page 42 of the Proxy Statement.

The Proxy Statement incorrectly stated that the vote required to approve Proposal No. 3 is “the affirmative vote of the majority of the shares present by remote communication or represented by proxy at the Annual Meeting and by the holders entitled to vote thereon to be approved.” However, Proposal No. 3 requires “the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the Annual Meeting by the holders entitled to vote thereon to be approved.”

Other than the revised language below, no other changes have been made to the Proxy Statement and it continues to be in full force and effect as originally filed with the SEC and the Board of Directors of the Company continues to seek the vote of Company stockholders on each of the proposals to be voted on at the Annual Meeting as recommended in the original filing.

Except as described in this supplement, the information provided in the Proxy Statement continues to apply. To the extent that information in this supplement differs from or updates information contained in the Proxy Statement, the information in this supplement is more current. The Proxy Statement contains additional information. This supplement should be read in conjunction with the Proxy Statement.

The Proxy Statement is hereby supplemented and amended as follows:

The disclosure provided in the section titled “Procedural Matters—How many votes are needed for approval of each proposal?” set forth on page 3 of the Proxy Statement with respect to Proposal No. 3, is hereby replaced in its entirety as follows:

“Proposal No. 3: The approval of the amendment to our 2022 Plan to (i) increase the number of shares authorized for issuance thereunder by 1,300,000 shares to 2,765,789 shares and (ii) increase the number of shares authorized for issuance thereunder pursuant to the exercise of ISOs to 2,765,789 shares requires the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the Annual Meeting by the holders entitled to vote thereon to be approved. Stockholder abstentions will not have any effect on the outcome of this proposal, so long as a quorum exists. Broker non-votes will have no effect on the outcome of this proposal.”


The disclosure provided in the section titled “Proposal No. 3 — Approval of the Amendment to the 2022 Plan — Vote Required” set forth on page 42 of the Proxy Statement, is hereby replaced in its entirety as follows:

“Vote Required

The approval of the Plan Amendment requires the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the Annual Meeting by the holders entitled to vote thereon to be approved. Stockholder abstentions will not have any effect on the outcome of this proposal, so long as a quorum exists. Broker non-votes will have no effect on the outcome of this proposal.”

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Scilex Holding Co (SCLX)

Reference

Frequently asked questions

When did Scilex Holding Co file this DEFA14A?
Scilex Holding Co (SCLX) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 5, 2026. The accession number assigned by EDGAR is 0001193125-26-206367.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Scilex corrects voting threshold for Proposal No. 3 and discloses plan to increase authorized shares under the 2022 Plan. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Scilex Holding Co's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Scilex Holding Co has filed under CIK 1820190, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer